Brazilian swimmer Etiene Medeiros faces the prospect of missing this year's Olympic Games after failing a doping test, local authorities confirmed.
The 25-year-old was found to have traces of fenoterol in her urine during an out-of-competition test last month. Results of a B sample confirmed the presence of the banned substance, reports Xinhua.
Fenoterol is banned by the World Anti-Doping Agency (WADA) because of its properties as a stimulant that increases hormone production.
"On June 15 the ABCD (Brazilian anti-doping authority) stated the facts to the CBDA (Brazilian swimming confederation) so that the confederation can begin disciplinary proceedings," the ABCD said in a statement.
Medeiros, who has qualified for the 50m freestyle, 100m freestyle and 100m backstroke at the Rio Olympics in August, said she unwittingly took the substance as part of her medication for asthma.
She is expected to appeal the decision in the coming days.
--IANS
tri/bg
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
